Get startedLog in
    Picture of Kodiak Sciences logo

    KOD — Kodiak Sciences News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeLarge CapMomentum Trap
    All News

    Brief: New One-Year Results For Kodiak's Tarcocimab Tedromer

    Picture of Kodiak Sciences logoKodiak Sciences
    07/09/2023 12:00
    Sept 7 (Reuters) - Kodiak Sciences Inc  KOD.O :
    * NEW ONE-YEAR RESULTS FOR KODIAK'S TARCOCIMAB TEDROMER IN
THE
PIVOTAL BEACON TRIAL REINFORCE DURABILITY SIGNAL AND DEMONSTRATE
MATCHED EFFICACY AND COMPARABLE SAFETY AND TOLERABILITY IN
RETINAL VEIN OCCLUSION
    * KODIAK SCIENCES: TARCOCIMAB SHOWED STRONG DURABILITY
    * KODIAK SCIENCES INC: TARCOCIMAB MATCHED EFFICACY AND
COMPARABLE
SAFETY VERSUS AFLIBERCEPT IN A HEAD-TO-HEAD COMPARATIVE PIVOTAL
TRIAL OVER ONE-YEAR

Source text for Eikon:  ID:nPn31NrcTa 
Further company coverage:  KOD.O 

 (Reporting by ArsheeyaSingh Bajwa)
 ((ArsheeyaSingh.Bajwa@thomsonreuters.com;))

    Recent news on Kodiak Sciences

    See all news